Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

[Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers].

Roumeguère T, Zouaoui Boudjeltia K, Hauzeur C, Ramal A, Schulman C, Vanhaeverbeek M, Ducobu J, Wespes E.

Prog Urol. 2008 Dec;18(13):1087-91. doi: 10.1016/j.purol.2008.09.057. Epub 2008 Nov 13. French.

PMID:
19041816
2.

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC; FIELD study investigators.

Diabetologia. 2010 Sep;53(9):1846-55. doi: 10.1007/s00125-010-1806-9. Epub 2010 Jun 6.

PMID:
20526762
3.

Apolipoproteins A-I and B-markers in coronary risk evaluation.

Agoston-Coldea L, Zdrenghea D, Pop D, Crăciun A, Rusu ML, Mocan T.

Rom J Intern Med. 2007;45(3):251-8.

PMID:
18333357
5.

Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.

Walldius G, Aastveit AH, Jungner I.

J Intern Med. 2006 Mar;259(3):259-66.

6.

The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease.

Khadem-Ansari MH, Rasmi Y, Rahimi-Pour A, Jafarzadeh M.

Singapore Med J. 2009 Jun;50(6):610-3.

8.

Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.

Juonala M, Viikari JS, Kähönen M, Solakivi T, Helenius H, Jula A, Marniemi J, Taittonen L, Laitinen T, Nikkari T, Raitakari OT.

J Am Coll Cardiol. 2008 Jul 22;52(4):293-9. doi: 10.1016/j.jacc.2008.03.054.

9.

Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.

Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G.

J Intern Med. 2006 May;259(5):455-61. Erratum in: J Intern Med. 2006 Aug;260(2):186. Junger, I [corrected to Jungner, I].

10.
11.
12.

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN.

Diabetologia. 2009 Feb;52(2):218-25. doi: 10.1007/s00125-008-1176-8. Epub 2008 Oct 30. Erratum in: Diabetologia. 2009 Mar;52(3):556.

PMID:
18972097
13.

ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW.

Curr Med Res Opin. 2008 Feb;24(2):359-64.

PMID:
18081989
14.

Body composition and the apoB/apoA-I ratio in migrant Asian Indians and white Caucasians in Canada.

Smith J, Cianflone K, Al-Amri M, Sniderman A.

Clin Sci (Lond). 2006 Sep;111(3):201-7.

PMID:
16712524
15.

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.

Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G.

Eur Urol. 2005 Feb;47(2):214-20; discussion 220-2.

PMID:
15661417
16.

Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study.

Leiviskä J, Sundvall J, Alfthan G, Jauhiainen M, Salomaa V.

Clin Chim Acta. 2011 May 12;412(11-12):1146-50. doi: 10.1016/j.cca.2011.03.015. Epub 2011 Mar 17.

PMID:
21419755
17.

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).

Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group.

Ann Med. 2008;40(6):456-64.

PMID:
19160529
18.

Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).

Holme I, Aastveit AH, Jungner I, Walldius G.

J Intern Med. 2008 Jul;264(1):30-8. doi: 10.1111/j.1365-2796.2008.01925.x. Epub 2008 Feb 21.

19.

Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up.

Johansson L, Schmidt C.

Angiology. 2009 Oct-Nov;60(5):539-45. doi: 10.1177/0003319708324925. Epub 2008 Nov 19.

PMID:
19022789
20.

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E.

Lancet. 2001 Dec 15;358(9298):2026-33.

PMID:
11755609

Supplemental Content

Support Center